The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.

Chan, Joseph; Jayamanne, Dasantha; Wheeler, Helen; Khasraw, Mustafa; Wong, Matthew; Kastelan, Marina; Guo, Lesley; Back, Michael

Chan, Joseph; Jayamanne, Dasantha; Wheeler, Helen; Khasraw, Mustafa; Wong, Matthew; Kastelan, Marina; Guo, Lesley; Back, Michael.

Afiliación

Chan J; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Jayamanne D; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Wheeler H; Sydney Medical School, University of Sydney, Sydney, Australia.
Khasraw M; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Wong M; Sydney Medical School, University of Sydney, Sydney, Australia.
Kastelan M; The Brain Cancer Group, Sydney, Australia.
Guo L; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.
Back M; Sydney Medical School, University of Sydney, Sydney, Australia.

Clin Transl Radiat Oncol ; 22: 33-39, 2020 May.

Article en En | MEDLINE | ID: mdl-32195378

Palabras clave

BEV, bevacizumab; Bevacizumab; CNS; ECOG, Eastern cooperative oncology group; Glioblastoma; OS, overall survival; Re-irradiation; ReRT, reirradiation; Recurrent glioma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Clin Transl Radiat Oncol Año: 2020 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Irlanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google